1. Measured by its ability to bind human VEGF-D in functional ELISA. 2. Immobilized human VEGF-C at 10 μg/mL (100 μL/well) can bind mouse VEGFR3-Fc. The EC50 of mouse VEGFR3-Fc is 0.008 μg/mL. 3. Measured by its ability to bind with mouse FIGF-His in a functional ELISA.

VEGFR3/FLT4 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 112 kDa and the accession number is P35917-1.

Mouse

HEK293 Cells

VEGFR-3,VEGFR3,fms related tyrosine kinase 4,Flt-4,Chy,AI323512

A DNA sequence encoding the mouse FLT4 (P35917-1) extracellular domain (Met 1-Glu 775) was was fused with the Fc region of human IgG1 at the C-terminus. Predicted N terminal: Tyr 25

> 92 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy